Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Disclosed amino acid sequence derived from bacterium (e.g., Mycoplasma, Anaplasma, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424184100 - ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)

424185100 - Amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110200631LAWSONIA INTRACELLULARIS VACCINES - The present invention relates to polynucleotide sequences encoding novel 08-18-2011
20080260768Streptococcus pneumoniae proteins and nucleic acid molecules - Protein antigens from 10-23-2008
20080260767Novel Protein Which can be Used, in Particular, for the In Vitro Isolation and Prevention of Legionella Pneumophila Infections - The invention relates to novel polynucleotides, including SEQ ID NO: 1 or parts or variants of the sequence, novel polypeptides encoded by the polynucleotides, expression vectors including the polynucleotides and host cells including the expression vectors. The polynucleotides and polypeptides can be used in the field of in vitro diagnosis and/or for production of vaccines against 10-23-2008
20090285847Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis - Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen 11-19-2009
20090269368PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS - This invention provides 10-29-2009
20120183570ANTIGEN COMPOSITIONS AND METHODS OF INHIBITING CAMPYLOBACTER JEJUNI BACTERIAL INFECTION AND USES OF THE ANTIGEN COMPOSITIONS - Methods and compositions for reducing the incidence of 07-19-2012
20090214584Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis - The present invention is directed toward isolated 08-27-2009
20130078271NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.03-28-2013
20100034846NOVEL METHOD FOR TREATING H.PYLORI INFECTIONS - The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ. ID. No. 1, whereby such region is defined by 02-11-2010
20130084304VACCINE AND METHODS TO REDUCE CAMPYLOBACTER INFECTION - Vaccine vectors and methods for enhancing resistance to 04-04-2013
20130034577Methods and Compositions for Vaccination Comprising Nucleic Acid and/or Polypeptide Sequences of Chlamydia - The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a 02-07-2013
20090155295VACCINE - A polypeptide derived from the periplasmic space of 06-18-2009
20100143394SYNTHETIC STREPTOCOCCUS PNEUMONIAE VACCINE - Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R206-10-2010
20130028926BIOSYNTHETIC SYSTEM THAT PRODUCES IMMUNOGENIC POLYSACCHARIDES IN PROKARYOTIC CELLS - The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.01-31-2013
20130028927METHOD OF DIAGNOSING AND TREATING MELIOIDOSIS - Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis. These methods include inducing an immune response to melioidosis and/or using an inhibitory nucleic acid, such as a siRNA or antisense molecule, to decrease a melioidosis associated molecule expression in order to treat melioidosis.01-31-2013
20090074807MORAXELLA (BRANHAMELLA) CATARRHALIS ANTIGENS - The present invention relates to polypeptides of 03-19-2009
20090053259VACCINES AND METHODS FOR TREATMENT OR PREVENTION OF GRAM NEGATIVE BACTERIAL INFECTION IN A VERTEBRATE SUBJECT - Methods for the treatment or prevention of Gram negative bacterial infection in a vertebrate subject are provided. The methods provide administering an antagonist of bacterial flagellar protein biosynthesis to the vertebrate subject in an amount effective to reduce or eliminate the bacterial infection. Methods for the treatment or prevention of 02-26-2009
20130101614NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS - Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.04-25-2013
20090304731RECOMBINANT ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SPOTTED FEVER RICKETTSIAE - The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group 12-10-2009
20090041797MODIFIED TOXINS - The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.02-12-2009
20120219578NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria 08-30-2012
20090285845Domains And Epitopes Of Meningococcal Protein NMB1870 - ‘NMB1870’ is a known surface protein in 11-19-2009
20130071423COMBINATION VACCINE FOR STREPTOCOCCUS - The invention relates to the use of a combination of SP03-21-2013
20130058967RECOMBINANT MODIFIED BACILLUS ANTHRACIS PROTECTIVE ANTIGEN FOR USE IN VACCINES - The invention relates to improved methods of producing and recovering sporulation-deficient 03-07-2013
20110014225CROSS-REACTIVE DETERMINANTS AND METHODS FOR THEIR IDENTIFICATION - Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive 01-20-2011
20110014224METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to 01-20-2011
20110014223MULTIMERIC PROTEINS ABLE TO INDUCE AN ANTIBODY RESPONSE AGAINST THE BETA-AMYLOID AND USE THEREOF - The present invention relates to the fields of molecular biology, immunology and medicine. Peptide sequences that belong to the beta amyloid peptide are exposed on the surface of a multimeric structure derived from the E2 component of alpha keto acid dehydrogenase. The molecules are useful for the production of vaccines for the treatment and/or prevention of Alzheimer's disease.01-20-2011
20120308596NOVEL STREPTOCOCCUS ANTIGENS - proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of 12-06-2012
20090274719CHLAMYDIA TRACHOMATIS GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION - The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of 11-05-2009
20130064846NEISSERIAL ANTIGENS - The invention provides proteins from 03-14-2013
20130064845BACTERIAL VACCINE COMPONENTS FROM STAPHYLOCOCCUS AUREUS AND USES THEREOF - Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the 03-14-2013
20110020384THERAPEUTIC TB VACCINE - Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing 01-27-2011
20110020383NOVEL GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF - Novel polynucleotide and amino acids of 01-27-2011
20090238842Vaccine for preventing and treating porcine progressive atrophic rhinitis - The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragments of recombinant subunit 09-24-2009
20090022753Surface proteins of streptococcus pyogenes - β-hemolytic streptococci polynucleotides, polypeptides, particularly 01-22-2009
20090010957Immunogenic Mycoplasma Hyopneumoniae Polypeptides - polypeptides and nucleic acids, as well as nucleic acid expression vectors and host cells containing nucleic acid vectors are provided. In addition, compositions containing 01-08-2009
20090010956EHRLICHIA EWINGII PROTEINS, NUCLEIC ACIDS, AND METHODS OF THEIR USE - The novel omp-1 gene cluster encoding twenty one 01-08-2009
20080305124ORAL PERTUSSIS VACCINE AND METHOD FOR PRODUCING PERTUSSIS VACCINE - The present invention is related to an oral pertussis vaccine and a method for producing pertussis vaccine, wherein the oral pertussis vaccine comprises amino acid sequence of 1094 to 1279 (SEQ ID NO.1) of filamentous hemagglutinin. The method for producing pertussis vaccine comprises following steps: constructing a vector comprising amino acid sequence of 1094 to 1279 (SEQ ID NO. 1) of filamentous hemagglutinin; transforming the vector into 12-11-2008
20120237537METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to 09-20-2012
20120237536COMBINATION VACCINES AGAINST RESPIRATORY TRACT DISEASES - Influenza, pneumococcus and/or RSV vaccines are administered as a combination vaccine while retaining immunogenic efficacy. This combination simplifies immunisation against these two lower respiratory tract infections. The pneumococcal vaccine ideally includes at least one pneumococcal polypeptide.09-20-2012
20130164317ANTIMICROBIAL AGENT, BACTERIAL STRAIN, BIOSYNTHESIS, AND METHODS OF USE - Provided herein is a biologically pure culture of 06-27-2013
20090092629VACCINE FOR NONTYPEABLE HAEMOPHILUS INFLUENZAE INFECTION - This invention provides a method for identifying strains of nontypeable 04-09-2009
20120100171HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS - This invention relates to immunogenic compositions for inducing an immune response against an antigen of interest. In particular, the invention provides immunogenic compositions comprising an antigen-carrier conjugate, wherein the carrier is a bacterial toxin that contains a signal peptide. The invention also provides methods of generating immunogenic compositions with enhanced immunogenicity, comprising adding a signal peptide to the bacterial carrier in an antigen-carrier conjugate, such as a hapten-carrier conjugate. The invention also provides methods for inducing an immune response to a hapten in a subject using these immunogenic compositions.04-26-2012
20110280900CLOSTRIDIUM CHAUVOEI POLYPEPTIDE, DNA ENCODING THE POLYPEPTIDE AND A VACCINE COMPRISING THE POLYPEPTIDE - The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of 11-17-2011
20110142870Bacillus anthracis antigens, vaccine compositions, and related methods - The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by 06-16-2011
20100047267Staphylococcus aureus proteins and nucleic acids - The invention provides proteins from 02-25-2010
20100015170FLAGELLIN MUTANT VACCINE - The present invention provides a vaccine which effectively induces protective immune response particularly against flagellated pathogens (such as 01-21-2010
20120288517Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof - Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of 11-15-2012
20130022633MENINGOCOCCAL fHBP POLYPEPTIDES - The factor H binding activity of meningococcal fHBP can be uncoupled from its bactericidal sensitivity. NMR studies have identified various amino acid residues involved in the fHBP/fH interaction and one or more of these residues is modified in a fHBP to reduce or eliminate its ability to bind to fH.01-24-2013
20110300171FACTOR H BINDING PROTEIN IMMUNOGENS - The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins.12-08-2011
20120189649Vaccines and Compositions Against Streptococcus Pneumoniae - is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in 07-26-2012
20110287046MODIFIED STREPTOCOCCUS PNEUMONIA PNEUMOLYSIN (PLY) POLYPEPTIDES - This disclosure relates to modified 11-24-2011
20120014982Methods and Compositions for Immunizing Against Chlamydia Infection - The present invention relates, in part, to methods and compositions for immunizing against infection by 01-19-2012
20110293652CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of 12-01-2011
20120189650IMMUNOGENIC COMPOSITION COMPRISING VARIANTS OF STAPHYLOCOCCAL CLUMPING FACTOR A - The present invention relates to ClfA polypeptides wherein amino acid Y474 or an amino acid adjacent to Y474 is mutated such that fibrinogen binding activity is decreased compared to an equivalent ClfA polypeptide without mutation of Y474 or an amino acid adjacent to Y474 as well as immunogenic compositions, vaccines, processes and uses of such mutated ClfA polypeptides.07-26-2012
20110262477Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a 10-27-2011
20100021492MORAXELLA CATARRHALIS OUTER MEMBRANE PROTEIN-106 POLYPEPTIDE, GENE SEQUENCE AND USES THEREOF - The invention discloses the 01-28-2010
20090060932Groups Of Borrelia Burgdorferi And Borrelia Afzelii That Cause Lyme Disease In Humans - The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing 03-05-2009
20090148469Multicomponent meningococcal vaccine - A composition is provided comprising 06-11-2009
20100129391IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two 05-27-2010
20100330113Vaccine Antigens - The present invention discloses novel proteins, e.g., antigens. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses vaccines that can be used to protect fish from 12-30-2010
20120107341METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to 05-03-2012
20120107340COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective 05-03-2012
20120107339Chimeric Factor H Binding Proteins (fHBP) Containing a Heterologous B Domain and Methods of Use - Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of 05-03-2012
20090274718CHIMERIC PROTEINS THAT INDUCE EFFECTS DIRECTED AGAINST VIRUSES - The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from 11-05-2009
20090280140Early detection of mycobacterial disease using peptides - A number of protein and glycoprotein antigens secreted by 11-12-2009
20090104218Group B Streptococcus - Polypeptides and nucleic acids from 04-23-2009
20090285848METHODS AND COMPOSITIONS FOR IMMUNIZING AGAINST PSEUDOMONAS INFECTION - Methods and compositions for inducing an immune response against 11-19-2009
20110171245RECOMBINANT ANTIGEN FOR DIAGNOSIS AND PREVENTION OF MURINE TYPHUS - The invention relates to a recombinant immunogenic composition from 07-14-2011
20090148470PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - The present invention is primarily directed to a method for preventing infection of a mammalian subject with 06-11-2009
20120294882MODIFIED TUBERCULOSIS ANTIGENS - Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.11-22-2012
20120269841COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant 10-25-2012
20090297549CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES - The invention relates to polynucleotides which are conserved or specific to one or more species of 12-03-2009
20090297548IMMUNOGENIC COMPOSITIONS COMPRISING ANTHRAX SPORE-ASSOCIATED PROTEINS - Compositions and methods for treating a 12-03-2009
20120294881PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide of 11-22-2012
20120294880NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to 11-22-2012
20080213294Immunization of dairy cattle with GapC protein against streptococcus infection - The GapC plasmin binding protein genes of 09-04-2008
20100136040USE OF THE 7F4 PROTEIN IN THE IN VITRO DIAGNOSIS OF MYCOPLASMA PNEUMONIAE INFECTIONS - A method for determining if an individual is infected by 06-03-2010
20080241182MYCOBACTERIUM TUBERCULOSIS PERSISTANCE GENES - Compositions and methods for preventing 10-02-2008
20080241181Environmentally regulated genes of Streptococcus suis - The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a 10-02-2008
20100272744OMP85 Proteins of Neisseria Gonorrhoeae and Neisseria Meningitidis, Compositions Containing Same and Methods of Use Thereof - Nucleic acid and amino acid sequences of the Omp85 proteins of 10-28-2010
20080279880PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI - This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A 11-13-2008
20080305125Mutant Forms Of EtxB and CtxB And Their Use As Carriers - The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.12-11-2008
20110268758TUBERCULOSIS ANTIGEN DETECTION ASSAYS AND VACCINES - The present invention relates to isolated Tuberculosis (TB) antigens that are useful in therapeutic and vaccine compositions for stimulating a TB specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active TB in an individual. Accordingly, the present invention includes polypeptide molecules, nucleic acid molecules, vaccine compositions, diagnostic assays, and methods of diagnosis and monitoring treatment related to these TB antigens.11-03-2011
20080311144MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT - Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.12-18-2008
20080311145PROTEIN CAGE IMMUNOTHERAPEUTICS - The present invention provides compositions of heat shock protein cages for use in therapeutic vaccines. The heat shock protein cages of the invention have attached antigen, located either on the interior or exterior of the protein cage, and optionally an adjuvant.12-18-2008
20080311146Immunogenic Composition - The present invention discloses an immunogenic composition comprising at least two different isolated staphylococcal polypeptides, each comprising an IgG binding domain. In a further embodiment, the invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain.12-18-2008
20110008379IMMUNOGENIC COMPOSITIONS CONTAINING ESCHERICHIA COLI H7 FLAGELLA AND METHODS OF USE THEREOF - Immunogenic compositions containing 01-13-2011
20090004217Ehrlichia canis DIVA (differentiate infected from vaccinated animals) - antigens that can be used to differentiate 01-01-2009
20100291132Streptococcus uberis adhesion molecule - A polypeptide, designated as “11-18-2010
20100291131CLOSTRIDIAL TOXIN NETB - The present invention relates to a polypeptide based toxin that originates from 11-18-2010
20120141522RECOMBINANT PROTECTIVE PROTEIN FROM STREPTOCOCCUS PNEUMONIAE - The present invention discloses amino acid sequences and nucleic acid sequences relating to a 06-07-2012
20110206713TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the 08-25-2011
20090136535ADJUVANT ACTIVITIES OF MUTANTS OF LT-IIa AND LT-IIb ENTEROTOXIN LACKING BINDING TO GANGLIOSIDE - The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant activity. These mutants are useful for enhancing immune response to antigens.05-28-2009
20090162391VACCINE ANTIGENS FROM PISCIRICKETTSIA SALMONIS - The present invention discloses novel proteins, e.g., antigens, from 06-25-2009
20090186048TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the 07-23-2009
20120070458ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.03-22-2012
20120070457Polypeptides from neisseria meningitidis - Polypeptides comprising 03-22-2012
20090155296MUTANTS OF LYSINE DECARBOXYLASE, VACCINES FOR PERIODONTITIS, AND METHODS OF USE - The present invention is directed to mutants of lysine decarboxylase, nucleic acids encoding the mutants, and vaccines comprising the mutants for inhibiting and reducing the development of periodontal diseases, including gingivitis and chronic periodontitis. The vaccine composition comprises a recombinant lysine decarboxylase mutant which is based on a native version of the enzyme from 06-18-2009
20090252756PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - Vaccine compositions and methods for protecting a mammalian subject against infection with 10-08-2009
20110223186Clostridium toxin, and process for the preparation of immunogenic composition - The present invention relates to the field of bacterial toxic proteins, in particular toxins from 09-15-2011
20090053258Assays for diagnosis of tuberculosis and uses thereof - The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines.02-26-2009
20110142871COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS - Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more 06-16-2011
20110229507STABLE ANTHRAX VACCINE FORMULATIONS - Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection.09-22-2011
20110229509POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - Disclosed are polypeptides comprising an amino acid sequence structurally related to SEQ ID NO 1 and uses of such polypeptides and compositions thereof. SEQ ID NO 1 is a full length 09-22-2011
20090208521PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEIN NMA0939 - The present invention is related to field of medicine, particularly to the development of pharmaceutical formulations containing NMA0939 protein. Formulations described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. NMA0939 protein was identified as a 08-20-2009
20090117142RECOMBINANT FUSOBACTERIUM NECROPHORUM LEUKOTOXIN VACCINE AND PREPARATION THEREOF05-07-2009
20090246219NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE) - The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in 10-01-2009
20090246218S. AUREUS FIBRINOGEN BINDING PROTEIN GENE - The isolation of genes and proteins from 10-01-2009
20100166793PROTEASE-RESISTANT MODIFIED SEB AND VACCINE CONTAINING THE SAME - A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.07-01-2010
20100015171VACCINES COMPRISING TB 10.4 - Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD401-21-2010
20120195920STAPHYLOCOCCUS AUREUS DIV1B FOR USE AS VACCINE - The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial infection.08-02-2012
20120195919HYBRID AND TANDEM EXPRESSION OF NEISSERIAL PROTEINS - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH08-02-2012
20100183656PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the 07-22-2010
20100260789PRODUCTS SPECIFIC TO PATHOGENIC STRAINS AND THEIR USE AS VACCINES AND IN IMMUNOTHERAPY - The invention relates to isolated antigenic polypeptides obtainable by a process comprising the steps of: 1—selecting on the basis of sequence analysis those of the polypeptides which are either located in the outermembrane or secreted by the bacteria, 2—identifying the genes coding for said polypeptides which are conserved in B2/D clinical isolates, 3—purifying the polypeptides identified in step 1, which are found in step 2 to be conserved in B2/D isolates, 4—testing the polypeptides for immunogenicity using animals models. Application for making vaccines compositions and immunotherapies.10-14-2010
20090117143Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens - An immunogenic composition comprising a recombinant protein comprising a 05-07-2009
20100183653Fusion Proteins Comprising CD4 Minimal Modules and Methods of Use Thereof - Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.07-22-2010
20100183654IMMUNOREACTIVE PROTEIN ORTHOLOGS OF EHRLICHIA CANIS AND E. CHAFFEENSIS - The present invention concerns gp36 immunoreactive compositions for 07-22-2010
20100260791CHLAMYDIA ANTIGENS - antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as 10-14-2010
20120093852NON-LIPIDATED VARIANTS OF NEISSERIA MENINGITIDIS ORF2086 ANTIGENS - The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B 04-19-2012
20110110967GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against 05-12-2011
20110110968Human optimized Bacillus anthracis protective antigen - The invention relates to a humanized nucleic acid construct from 05-12-2011
20100221279KENNEL COUGH VACCINE - Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior to killing thereof. The protective protein(s) are operable to prevent or reduce the severity of a disease of the subject. The vaccine preparations of the invention do not require separation of the protective protein(s) from the host recombinant microorganism(s), thereby materially decreasing the complexity and cost of the vaccine formulations. A preferred vaccine against kennel cough includes recombinantly modified microorganisms which express protective antigens containing pertactin and filamentous hemagglutinin protein products.09-02-2010
20130216568IMMUNOGENIC PROTEINS AND COMPOSITIONS - The invention provides proteins and compositions for the treatment and prevention of 08-22-2013
20100136041COMBINATION GAS VACCINES AND THERAPEUTICS - Compositions useful for reducing the risk of, preventing, and/or treating 06-03-2010
20120141521Immunogenic Compositions for Streptococcus agalactiae - The invention relates to immunogenic polypeptides derived from epitopes in a 06-07-2012
20120141523IMMUNOGENIC COMPOSITION COMPRISING ANTIGENIC S. AUREUS PROTEINS - The present application relates to an immunogenic composition comprising a fragment of a staphylococcal Isd protein such as IsdA, IsdB, IsdC or IsdH which comprises a NEAT domain. Fusion proteins comprising a NEAT domain of a first staphylococcal Isd protein and a NEAT domain from a second Isd protein are also disclosed as well as fusion proteins comprising a NEAT domain of a staphylococcal Isd protein involved in an iron/heme uptake system and a ligand binding domain of a staphylococcal extracellular component binding protein, for example ClfA, ClfB, SdrC, SdrD or SdrE.06-07-2012
20090041796Surface protein of leptospira - The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods.02-12-2009
20090074806NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides isolated polypeptide and nucleic acid sequences derived from 03-19-2009
20090274717Genes and proteins, and their use - According to the present invention, a series of genes are identified in Group B 11-05-2009
20110027304YERSINIA PESTIS ANTIGENS, VACCINE COMPOSITIONS AND RELATED METHODS - The present invention provides antigens and vaccines useful in prevention of infection by 02-03-2011
20100221278IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.09-02-2010
20090162392MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against 06-25-2009
20130129764COMPOSITIONS AND METHODS TO DETECT VARIOUS INFECTIOUS ORGANISMS - The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm (05-23-2013
20130129765Compositions and Methods for Stimulating Immune Response Against Moraxella Catarrhalis - This invention provides a method for stimulating in an individual an immune response against 05-23-2013
20130136760STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS - The present invention relates to antigens, more particularly antigenS of 05-30-2013
20130136761S. PNEUMONIAE ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from 05-30-2013
20130136762MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a 05-30-2013
20090074808Secreted Streptococcus Pneumoniae Proteins - Novel proteins from 03-19-2009
20110110969PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI - This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A 05-12-2011
20110110966NOVEL IMMUNOGENIC PROTEINS OF LEPTOSPIRA - The invention provides novel immunogenic proteins LigA and LigB from 05-12-2011
20090068218Antigens for Vaccination Against and Detection of Mycoplasma Suis - The present invention relates to antigens for vaccination against and detection of 03-12-2009
20090068217Recombinant vaccine for preventing and treating porcine atrophic rhinitis - Disclosed is a recombinant vaccine for porcine atrophic rhinitis. A vaccine is provided which uses a 03-12-2009
20090068216MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a 03-12-2009
20110008378MODIFIED FLAGELLIN IMPROVED TOLL-LIKE RECEPTOR 5 STIMULATING ACTIVITY - Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.01-13-2011
20110033491MULTICOMPONENT MENINGOCOCCAL VACCINE - A composition is provided comprising 02-10-2011
20110243978ENTEROCOCCUS ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from 10-06-2011
20110150916COMPOSITIONS AND METHODS FOR TREATMENT OF GROUP A STREPTOCOCCI - Immunogenic compositions and vaccines are described comprising GAS Markers including AtmB Proteins. Methods for detecting GAS diseases in a subject are also described comprising measuring GAS markers or antibodies against GAS markers in a sample from the subject. The invention further provides kits for carrying out the methods of the invention and therapeutic applications for GAS diseases employing GAS markers, polynucleotides encoding the markers, and/or binding agents for the markers.06-23-2011
20110212120Ykur polynucleotides and polypeptides - Nucleic acid encoding a novel bacterial polypeptide ykuR, the isolated ykuR polypeptide, its expression from host cells, and its use in screening for potential antibacterial agents. Inhibition of ykuR activity results in inhibition of bacterial growth.09-01-2011
20110243977SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES - β-hemolytic streptococci polynucleotides, polypeptides, particularly 10-06-2011
20110243976COMPOSITIONS COMPRISING PNEUMOCOCCAL ANTIGENS - Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens.10-06-2011
20090220538 VACCINE FOR STAPHYLOCOCCAL INFECTIONS - The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.09-03-2009
20110212121RECOMBINANT CHIMERIC ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SCRUB TYPHUS - Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections.09-01-2011
20110250222ANTIGENIC POLYPEPTIDES OF CHLAMYDIA-RELATED BACTERIA FOR DIAGNOSIS AND VACCINE - The present invention relates to the disclosed transgenic peptides for use in the diagnosis of an infection by intracellular 10-13-2011
20130156802Cholera Toxin Chimera and its Use as a Staph Vaccine - The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of 06-20-2013
20130156804Porin B (PorB) as a Therapeutic Target for Prevention and Treatment of Infection by Chlamydia - The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit 06-20-2013
20100055124BRACHYSPIRA PILOSICOLI 72kDa OUTER-MEMBRANE PROTEIN AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - The invention relates to 03-04-2010
20100055123VACCINE AGAINST BURKHOLDERIA INFECTIONS - This invention relates to proteins expressed by ABC system genes of 03-04-2010
20090028891Chlamydia Antigens and Uses Thereof - The invention provides protein and nucleic acid sequences of 01-29-2009
20110076299NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to 03-31-2011
20110076300Hybrid Polypeptides Including Meningococcal fHBP Sequences - fHBP is a protein in 03-31-2011
20110076301ANTIGENIC PROTEIN FRAGMENTS OF STREPTOCOCCUS PNEUMONIAE - Antigenic protein fragments of 03-31-2011
20120148619ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.06-14-2012
20120148618MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NMB1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.06-14-2012
20120148617MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NBM1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.06-14-2012
20120148615POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE - Polypeptides comprising non-typeable 06-14-2012
20120148614Interaction of Moraxella Catarrhalis with Epithelial Cells, Extracellular Matrix Proteins and the Complement System - The present disclosure relates to surface proteins of 06-14-2012
20110059119IMMUNOGEN AGAINST CAMPYLOBACTER INFECTION - The invention relates to the use of 03-10-2011
20110033492VACCINES FOR BRUCELLOSIS - A polypeptide selected from the group consisting of BMEII0923, BMEI0411, a protective fragment of BMEII0923 and BMEI0411 and immunologically active variants of BMEII0923 and BMEIO411, which provides a protective immune response against 02-10-2011
20100310593Vaccines Against Chlamydia Infection - The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a 12-09-2010
20100297162S. EPIDERMIDIS ANTIGENS - Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of 11-25-2010
20120034258POLYPEPTIDES AND IMMUNIZING COMPOUNDS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a 02-09-2012
20090022756Recombinant F1-V Plague Vaccine - Disclosed herein is a composition comprising a purified fusion protein comprising all or part of F1 antigen of 01-22-2009
20110250221Group A Streptococcus Pharmaceutical Compositions and Methods Thereof - Isolated proteins and immunogenic fragments thereof, for use in the treatment and prevention of a Group A 10-13-2011
20110159026COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO FLAGELLATED BACTERIUM - Vaccines comprising fliC and CD 154 polypeptides and 06-30-2011
20110150918TREATMENT OF MICROBIAL INFECTIONS - The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy.06-23-2011
20090022754Recombinant antigen for diagnosis and prevention of murine typhus - The invention relates to a recombinant immunogenic composition from 01-22-2009
20080248056Immunomodulatory Product Obtained from a Bifidobacterium Culture and Compositions Containing the Same - The invention relates to an immunomodulatory product obtained from a 10-09-2008
20110150917Small Cationic Antimicrobial Peptides - Cationic bacteriocin and lantibiotic peptides are provided and their immunomodulatory activities are described. Methods are provided for selectively enhancing innate immunity. Other methods are provided for selectively suppressing a proinflammatory response. Other methods are provided for identifying a compound or compounds which modulate an innate immune response. Pharmaceutical compositions comprising the cationic bacteriocin and lantibiotic peptides or polynucleotides are also provided.06-23-2011
20090324633Immunogens from Uropathogenic Escherichia Coli - Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic 12-31-2009
20090317421COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL BACTERIUM PROTEINS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a 12-24-2009
20090317420Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae - The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B 12-24-2009
20090169577METHOD FOR STIMULATING IMMUNE RESPONSE AGAINST MORAXELLA CATARRHALIS - Provided is a method for stimulating in an individual an immune response against 07-02-2009
20120201844NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to 08-09-2012
20090110691Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) - The invention provides 04-30-2009
20080220010Immunogenic Compositions for Streptococcus Agalactiae - This application relates to Group B 09-11-2008
20110262475LYME DISEASE VACCINE - Antigenic polypeptides comprising linear immunodominant epitopes of 10-27-2011
20110020386VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE - is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in 01-27-2011
20110020382Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics - The invention provides isolated polypeptide and nucleic acid sequences derived from 01-27-2011
20110020385COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES - Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.01-27-2011
20100285048USE OF FLAGELLIN IN THE IMMUNOTHERAPY OF YERSINIA PESTIS - The invention provides a fusion protein comprising a flagellin adjuvant and a 11-11-2010
20100285047THERAPEUTICS AND DIAGNOSTICS FOR GROUP A STREPTOCOCCI - Immunogenic compositions and vaccines are described comprising GAS Markers. Methods for detecting GAS diseases in a subject are also described comprising measuring GAS markers in a sample from the subject. The invention further provides kits for carrying out the methods of the invention and therapeutic applications for GAS diseases employing GAS markers, polynucleotides encoding the markers, and/or binding agents for the markers.11-11-2010
20110256166Multivalent vaccines comprising recombinant viral vectors - The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.10-20-2011
20110052620HYBRID POLYPEPTIDES COMPRISING GBS-80 AND SPB1 PROTEINS OF STREPTOCOCCUS - GBS antigens GBS-80 and Spb1 are expressed in a single polypeptide chain, preferably with Spb1 upstream of GBS-80. Thus the invention provides a polypeptide comprising an amino acid sequence NH03-03-2011
20100183655Immunogenic Protein Constructs - Bacterial immunity proteins are utilized to increase immune response to an antigen of interest.07-22-2010
20120121639PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the 05-17-2012
20100322955VIRULENCE GENES, PROTEINS, AND THEIR USE - A series of genes from 12-23-2010
20090202578SURFACE PROTEINS FROM COAGULASE-NEGATIVE STAPHYLOCOCCI AND STAPHYLOCOCCUS AUREUS THAT GENERATE CROSS-REACTIVE MONOCLONAL AND POLYCLONAL ANTIBODIES - Surface proteins are provided which generate polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive 08-13-2009
20110097354SYSTEM FOR THE EXPRESSION OF PEPTIDES ON THE BACTERIAL SURFACE - Expression system of peptides on the bacterial surface characterised in that membrane-binding region the conserved sequence of the MSP1a protein of 04-28-2011
20110177111PROTECTIVE VACCINE AGAINST STAPHYLOCOCCUS AUREUS BIOFILMS COMPRISING CELL WALL-ASSOCIATED IMMUNOGENS - Vaccine formulations effective against 07-21-2011
20100166792Antigenic Polypeptides - The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; recombinant methods to manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides.07-01-2010
20100158935MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against 06-24-2010
20100196410Streptococcus pneumoniae Antigens and Vaccines - The present invention relates to novel vaccines for the prevention or attenuation of infection by 08-05-2010
20100196409BASB006 POLYPEPTIDES FROM NEISSERIA MENINGITIDIS AND IMMUNOGENIC COMPOSITIONS THEREOF - The invention provides BASB006 polypeptides and polynucleotides encoding BASB006 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.08-05-2010
20100068219PEPTIDES THAT MIMIC NON-HUMAN CROSS-REACTIVE PROTECTIVE EPITOPES OF THE GROUP B MENINGOCOCCAL CAPSULAR POLYSACCHARIDE - Peptides that mimic the antigenic features of non human-cross-reactive protective epitopes of the MenB CP and nucleic acids encoding the peptide mimetics are disclosed. Antibodies elicited by these peptides do not bind to polysialic acid in host tissue and thus provide a safe and efficacious method for the treatment and/or prevention of Meningitis B.03-18-2010
20090175894METHODS AND MATERIALS FOR PRODUCING A GENERIC ANTI-AMYLOID IMMUNE RESPONSE IN MAMMALS - Compositions containing fibrillar aggregates of amyloidogenic polypeptides and adjuvants are described as well as methods of using such compositions to induce generic anti-amyloid immune responses in mammals.07-09-2009
20100189738PORIN B (PorB) AS A THERAPEUTIC TARGET FOR PREVENTION AND TREATMENT OF INFECTION BY CHLAMYDIA - The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit 07-29-2010
20100189737Meningococcal vaccines including hemoglobin receptor - The meningococcal haemoglobin receptor, HmbR, is used as a vaccine antigen in combination with one or more further antigens e.g. in combination with a meningococcal outer membrane vesicle, with another purified meningococcal antigen (e.g. fHBP, 287, NadA, NspA, NhhA, App, Omp85, LOS), with a conjugated meningococcal capsular saccharide, etc.07-29-2010
20110189217METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE - This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided.08-04-2011
20120064105Engineered Type IV Pilin of Clostridium difficile - The present invention relates to engineered 03-15-2012
20120064104COMBINATIONS INCLUDING PNEUMOCOCCAL SEROTYPE 14 SACCHARIDE - Meningococcal lipooligosaccharide and pneumococcal serotype 14 capsular saccharide share an antigen that can cross-react with human tissue. The invention provides various ways of minimising the production of autoreactive antibodies when these two antigens are co-administered.03-15-2012
20120308595Novel Immunogenic Compositions For The Prevention And Treatment of Meningococcal Disease - The present invention relates to 12-06-2012
20090123491Novel method for preventing or treating M tuberculosis infection - The present invention is directed to methods of preventing reactivation of active and latent 05-14-2009
20100255022VACCINE AGAINST CLOSTRIDIUM PERFRINGENS - There is provided a vaccine for controlling 10-07-2010
20110008380Anaplasma Phagocytophilum (Aph) Antigens and Antibodies Specific for Anaplasma - The invention provides methods and compositions for the detection and treatment of 01-13-2011
20110117119NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c protein sequence for use in the treatment or prevention of latent TB. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of latent tuberculosis.05-19-2011
20120064103COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEIN AND PNEUMOCOCCAL SACCHARIDE CONJUGATES - An immunogenic composition comprising: (i) a conjugated pneumococcal capsular saccharide; and (ii) a meningococcal factor H binding protein (fHBP) antigen, and not including meningococcal outer membrane vesicles, is useful for immunising a subject against bacterial meningitis.03-15-2012
20110070256Vaccine Antigens from Piscirickettsia Salmonis - The present invention discloses novel proteins, e.g., antigens, from 03-24-2011
20120148616NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from 06-14-2012
20110305721COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more 12-15-2011
20080267990TB DIAGONOSTIC BASED ON ANTIGENS FROM M. TUBERCULOSIS - The present invention is based on the identification and characterization of a number of novel 10-30-2008
20100221277CHLAMYDIA PNEUMONIAE ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding hyperimmune serum-reactive antigens and fragments thereof, including hyperimmune serum-reactive antigens and fragments thereof derived from 09-02-2010
20120039925TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION - The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (02-16-2012
20120039924COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE - Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.02-16-2012
20110064761NOVEL SEQUENCES OF BRACHYSPIRA, IMMUNOGENIC COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF - Novel polynucleotide and amino acids of 03-17-2011
20120156236NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from 06-21-2012
20120301495ANTIGEN PEPTIDE AND USE THEREOF - In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes.11-29-2012
20120301496NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to 11-29-2012
20110318378Peptides Presenting an Epitope of a Domain of Factor H Binding Protein and Methods of Use - Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of 12-29-2011
20120308597SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION - Regions of 12-06-2012
20120207777DETOXIFIED ESCHERICHIA COLI IMMUNOGENS - Detoxified variants of the pathogenic 08-16-2012
20120003258MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against 01-05-2012
20120003256TUBERCULOSIS ANTIGENS, IMMUNOGENIC COMPOSITIONS, DIAGNOSTICS AND METHODS RELATED TO THE SAME - Provided herein are Mtb polynucleotides, recombinant Mtb peptides and polypeptides, immunogenic Mtb antigens, and Mtb antibodies. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides kits comprising Mtb polynucleotides, Mtb polypeptides, Mtb antibodies, and combinations thereof.01-05-2012
20120207778NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B - The invention provides proteins from group B 08-16-2012
20120207779Anaplasma phagocytophilum (Aph) Antigens and Antibodies Specific for Anaplasma - The invention provides methods and compositions for the detection and treatment of 08-16-2012
20120207776CONSERVED ESCHERICHIA COLI IMMUNOGENS - Homologs of the 08-16-2012
20120014983 RECOMBINANT ALPHA-HEMOLYSIN POLYPEPTIDE OF STAPHYLOCOCCUS AUREUS, HAVING A DELETION IN THE STEM DOMAIN AND HETEROLOGOUS SEQUENCES INSERTED - It refers to a recombinant alpha-hemolysin polypeptide of 01-19-2012
20090136534NOVEL RECOMBINANT BCG TUBERCULOSIS VACCINE DESIGNED TO ELICIT IMMUNE RESPONSES TO MYCOBACTERIUM TUBERCULOSIS IN ALL PHYSIOLOGICAL STAGES OF INFECTION AND DISEASE - A vaccine against 05-28-2009
20100136039BORRELIA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from 06-03-2010
20120114687TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (05-10-2012
20120114686COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS - Disclosed are methods and compositions for treating or preventing a 05-10-2012
20120114685COMPOSITIONS COMPRISING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF - The present invention provides recombinant 05-10-2012
20120114684COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a 05-10-2012
20100260790S. Pneumoniae Antigens - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from 10-14-2010
20100203075CHLAMYDIA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen from a 08-12-2010
20110104194IMMUNODOMINANT MYCOBACTERIUM TUBERCULOSIS PEPTIDES FROM CELL WALL PROTEINS FOR EARLY DIAGNOSIS AND IMMUNIZATION - A number of peptide epitopes and fragments from three 05-05-2011
20110104193COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a 05-05-2011
20120121638Polypeptide Derived From Enterococcus And Its Use For Vaccination - A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an 05-17-2012
20120121637CHIMERIC FACTOR H BINDING PROTEINS (FHBP) AND METHODS OF USE - Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of 05-17-2012
20100247561POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length 09-30-2010
20100247560MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF - Modified polypeptides based on the 09-30-2010
20120164166NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from 06-28-2012
20120128709EXPRESSION OF RECOMBINANT PROTEINS - The invention provides auto-inducible systems for expressing recombinant proteins of interest which take advantage of elements of quorum sensing (QS) systems of certain bacteria. These systems can be used to produce commercial quantities of proteins such as antigens, which can be used to prepare pharmaceutical compositions.05-24-2012
20120128707STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACIDS - The invention provides proteins and nucleic acid sequences from 05-24-2012
20110182924PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the 07-28-2011
20110182923NOVEL GROUP B STREPTOCOCCUS ANTIGENS07-28-2011
20120315292IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.12-13-2012
20120135026COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a 05-31-2012
20120135027PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS - Chimera proteins including: (i) at least one sequence of a DbpA protein of a 05-31-2012
20120135024NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from 05-31-2012
20120135025CHLAMYDIA ANTIGENS AND USES THEREOF - The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., T cell-mediated and/or B cell-mediated immune responses). The present invention provides methods of prophylaxis and/or treatment of chlamydia-mediated diseases comprising administering an immunogenic composition including one or more of the novel antigens described herein.05-31-2012
20100172927Vaccines Against Chlamydial Infection - Methods and compositions for the treatment or prevention of ocular 07-08-2010
20100172926ANTHRAX COMPOSITIONS AND METHODS OF USE AND PRODUCTION - Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by 07-08-2010
20120251565COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING BURKHOLDERIA INFECTION - The present invention provides a protein or a fragment or a variant of said protein, wherein the protein, fragment, or variant is capable of producing a protective immune response in an animal, wherein the immune response is protective against infection by 10-04-2012
20120171238S. AUREUS ALLERGEN - The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with 07-05-2012
20120171237RECOMBINANT CHIMERIC ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SCRUB TYPHUS - Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections.07-05-2012
20120171236IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE - The published genomic sequence of 07-05-2012
20110206712TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.08-25-2011
20120076814COMBINATIONS OF PNEUMOCOCCAL RRGB CLADES - Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.03-29-2012
20120076813USES OF GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS - The present invention relates to polypeptide fragments, including variants and analogs, of 03-29-2012
20120177678COMPOSITIONS AND METHODS FOR TREATMENT OF CERVICAL DYSPLASIA - The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a recombinant 07-12-2012
20120177680POLYPEPTIDES AND METHODS FOR THE SPECIFIC DETECTION OF ANTIBODIES IN PATIENTS WITH A BORRELIA INFECTION - The present disclosure relates to proteins derived from OspC from bacteria of the genus 07-12-2012
20120177679MATRIX METALLOPROTEINASE 11 VACCINE - Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.07-12-2012
20100272743Staphylococcus epidermidis nucleic acids and proteins - polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides and DNA (RNA) for the treatment of infection, particularly infections arising from 10-28-2010
20100008943EXTRACELLULAR MATRIX-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS - An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of 01-14-2010
20100008942Histophilus Somni Polynucleotides, Polypeptides and Methods of Use - This invention provides, among other things, protein, polypeptides, and fragments thereof, derived from bacteria 01-14-2010
20090060934S. AGALACTIAE ANTIGENS I & II - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from 03-05-2009
20090060933PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.03-05-2009
20120225091MODIFIED LIVE (JMSO STRAIN) HAEMOPHILUS PARASUIS VACCINE - The present invention is a live vaccine from a culture of cells of 09-06-2012
20120258128Infection Factor Assay - There is provided a method of selecting an anti-macrophage micro-organism comprising an anti-macrophage factor, the method comprising the steps of: 10-11-2012
20090017054NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides isolated polypeptide and nucleic acid sequences derived from 01-15-2009
20080299142COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a 12-04-2008
20120263745ANTICHLAMYDIAL AGENTS - An antichlamydial agent comprising an inhibitor of Chlamydial Protease-like Activity Factor (CPAF). The inhibitor of CPAF can comprise a CPAF inhibitory segment and can optionally include one or more additional residues or domains. Also provided are compositions comprising an inhibitor of CPAF, methods of identifying an inhibitor of CPAF, and methods of treating a 10-18-2012
20120328644Low Antigen-dose Immunization for Maximizing T-helper Cell 1 (Th1) Immunity Against a Pathogen - Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response.12-27-2012
20120328643OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) 12-27-2012
20120328642BOTULINUM NEUROTOXIN ANTIGENIC COMPOSITIONS AND METHODS - Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.12-27-2012
20110045012ANTI-ATHEROMA VACCINE - The invention relates to a recombinant protein comprising: a carrier portion; a first epitope capable of eliciting an anti-atheroma response; and a second epitope capable of eliciting an anti-atheroma response, characterised in that said first and second epitopes are distinct from one another.02-24-2011
20110045011TRUNCATED RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN ANTIGEN (R56) OF ORIENTIA TSUTSUGAMUSHI STRAINS KARP, KATO and GILLIAM AND ITS USE IN ANTIBODY BASED DETECTION ASSAYS AND VACCINES - A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, 02-24-2011
20120269843S. EPIDERMIDIS ANTIGENS - Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of 10-25-2012
20120269842ENTEROTOXIGENIC E. COLI FUSION PROTEIN VACCINES - The disclosure relates to fusions of enterotoxigenic 10-25-2012
20120128708DIAGNOSTIC MYCOBACTERIUM TUBERCULOSIS TEST - A method of diagnosing 05-24-2012
20120321657GROUP A STREPTOCOCCUS MULTIVALENT VACCINE - Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A 12-20-2012
20120321656OLIGOPEPTIDES AND THEIR USE FOR TREATING INFECTIOUS DISEASES - The invention discloses identification, method of making and therapeutic use of synthetic oligopeptides for the treatment of infectious diseases, in particular tuberculosis. The oligopeptides are designed using virulence mediating protein for 12-20-2012
20120282289STAPHYLOCOCCAL ANTIGENS - The present invention provides novel sequences encoding 11-08-2012
20120282290Mycobacterial Vaccines - There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.11-08-2012
20100215684STREPTOCOCCUS M PROTEIN, IMMUNOGENIC FRAGMENTS, NUCLEIC ACIDS AND METHODS OF USE - Isolated M proteins, or M-like proteins, of 08-26-2010
20100215683PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS HYPERVIRULENT STRAINS - The invention provides protective antigens for Group B streptococcus hypervirulent strains. The fragments are useful in vaccine compositions to induce protection against 08-26-2010
20120100172IMMUNOGENIC STREPTOCOCCUS PNEUMONIAE PEPTIDES AND PEPTIDE-MULTIMERS - The present invention relates to immunogenic peptides, including variants and analogs derived from 04-26-2012
20130011428NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF - The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of 01-10-2013
20130017214BACTEREMIA-ASSOCIATED ANTIGEN FROM STAPHYLOCOCCUS AUREUSAANM Edgeworth; JonathanAACI LondonAACO GBAAGP Edgeworth; Jonathan London GB - The BAA antigen of 01-17-2013
20130017215SECRETED CAMPYLOBACTER FLAGELLA COREGULATED PROTEINS AS IMMUNOGENS - The invention relates to an immunogenic composition composed of secreted polypeptides derived from 01-17-2013
20110159027S. AGALACTIAE ANTIGENS I & II - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from 06-30-2011
20130022634NEW COMPOSITION AND METHODS FOR TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES - The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically, the invention relates to new immunomodulating complexes that are fusion proteins comprising a mutant subunit of the A1-subunit of the cholera toxin (CTA1), a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease. In the mutant CTA1 subunit, the amino acids corresponding to the amino acid 7, arginine, and amino acid 187, cysteine, in the native CTA1 have been replaced.01-24-2013
20130171183COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a 07-04-2013
20110262476MUTANT BACTERIAL GLYCOPROTEINS AND USES THEREOF - The present invention relates to the use of mutant glycoproteins from pathogenic bacteria lacking one or more phosphorylcholine and/or glycosylation post-translational modifications as immunogens. These post-translational modifications act as masking structures that elicit an immune response which does not confer protection on an infected individual. The removal or modification of these masking structures alters the protein such that it elicits a stronger immune response to the protein and/or the bacterial pathogen. Particular examples are pilin proteins and nitrite reductase glycoproteins of 10-27-2011
20130171184VACCINE AGAINST N. MENINGITIDIS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention comprise the Hsf (also called Msf) and Opc neisserial antigens. These antigens have been found to be the two mechanisms by which 07-04-2013
20080241180Liquid Vaccines For Multiple Meningococcal Serogroups - Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.10-02-2008
20090022755VACCINES AGAINST CHLAMYDIAL INFECTION - The present invention relates to compositions comprising proteins or polynucleotides of 01-22-2009
20120093851CHLAMYDIA ANTIGENS - The invention provides 04-19-2012
20120093850COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective 04-19-2012
20110268757USE OF PHENOL-SOLUBLE MODULINS FOR VACCINE DEVELOPMENT - The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer11-03-2011
20130115237THERAPEUTIC IMMUNIZATION IN HIV INFECTED SUBJECTS TO AUGMENT ANTIRETROVIRAL TREATMENT - The present invention generally relates to HIV compositions and methods of use. One aspect of the present invention relates to a composition comprising a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprising an HIV polypeptide or fragment thereof and a 05-09-2013
20130095132TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (04-18-2013
20130115238MENINGOCOCCAL FHBP POLYPEPTIDES - fHBP is a protein in 05-09-2013
20130101613PROTECTIVE PROTEINS OF S. AGALACTIAE, COMBINATIONS THEREOF AND METHODS OF USING THE SAME - The invention relates to a composition comprising at least two protective proteins against 04-25-2013
20130101615METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS - This invention is a method for immunizing, preventing or treating a 04-25-2013
20130122034STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED THEREON - The novel protein SA1789 from 05-16-2013
20130129763INTERACTION OF MORAXELLA CATARRHALIS WITH EPITHELIAL CELLS, EXTRACELLULAR MATRIX PROTEINS AND THE COMPLEMENT SYSTEM - The present disclosure relates to surface proteins of 05-23-2013
20090285846MUTANTS OF CHOLESTEROL-DEPENDENT CYTOLYSINS AND USES THEREOF - Mutants of cholesterol-dependent cytolysins comprising at least one amino acid substitution in at least one of Loop 1, Loop 2, or Loop 3 of Domain 4, nucleic acids encoding such polypeptide mutants, and compositions and vaccines comprising such polypeptide mutants.11-19-2009
20080206269Bacterial pheromones and uses thereof - RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described08-28-2008
20090280141Streptococcal Genes - Peptides derived from 11-12-2009
20130156803COMPOSITIONS AND METHODS RELATED TO P6 - Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM.06-20-2013
20130156805CHIMERIC MOMP ANTIGEN - The present invention regards polypeptides capable of eliciting an immunological response that is protective against 06-20-2013
20110229508POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length 09-22-2011
20130149327YERSINIA PESTIS ANTIGENS, VACCINE COMPOSITIONS, AND RELATED METHODS - The present invention provides antigens and vaccines useful in prevention of infection by 06-13-2013
20130122033FIMH VACCINE AGAINST URINARY TRACT INFECTIONS (UTI) - A engineered bacteriophage is herein described, displaying at its surface multiple copies of a polypeptide, which comprises a domain of the bacterial adhesion protein FimH fused with the coat protein pVIII. The domain is preferably the region 45-159aa of the mature protein FimH. The polypeptide beingantigenic, raises a desired immunological response, in particular against urinary tract infections (UTI) in a human or animal. The engineered bacteriophage is therefore suitable for the preparation of vaccinesfor therapy, diagnosis and/or prevention of urinary tract infections (UTI) in a human or animal.05-16-2013
20110236410KLEBSIELLA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a 09-29-2011
20110250223HYBRID AND TANDEM EXPRESSION OF NEISSERIAL PROTEINS - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH10-13-2011
20130149324THERAPEUTIC TB VACCINE - Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.06-13-2013
20130149326ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.06-13-2013
20130149325PORPHYROMONAS GINGIVALIS POLYPEPTIDES AND NUCLEOTIDES - The present invention relates to isolated 06-13-2013
20120276130DIAGNOSTIC AND THERAPEUTIC METHODS FOR RHEUMATIC HEART DISEASE BASED UPON GROUP A STREPTOCOCCUS MARKERS - This invention is in the field of identifying patients having rheumatic heart disease (RHD) associated with 11-01-2012
20120276129NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria 11-01-2012
20100316662Methods and Compositions for Vaccination Comprising Nucleic Acid and/or Polypeptide Sequences of Chlamydia - The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a 12-16-2010
20100068220BIOINFORMATIC METHOD FOR IDENTIFYING SURFACE-ANCHORED PROTEINS FROM GRAM-POSITIVE BACTERIA AND PROTEINS OBTAINED THEREBY - A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as 03-18-2010
20120282288Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides - Recombinant carrier molecules having amino acid sequences from thermostable enzymes and methods of use for expression, recovery and delivery of foreign sequences (peptides and polypeptides) produced in different systems (bacteria, yeast, DNA, cell cultures such as mammalian, plant, insect cell cultures, protoplast and whole plants in vitro or in vivo are provided. The recombinant carrier molecule using sequences from lichenase B (Lic B) were also made and used as part of carrier protein to express, recover and deliver a variety of target polypeptides of interest.11-08-2012
20130183330RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing 07-18-2013
20130183331IMMUNOGENIC PROTEINS FROM GENOME-DERIVED OUTER MEMBRANE OF LEPTOSPIRA AND COMPOSITIONS AND METHODS BASED THEREON - outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the 07-18-2013
20110311570PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the 12-22-2011
20130189295COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEINS - The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence.07-25-2013
20120003257RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing 01-05-2012
20120027793COMPOSITIONS COMPRISING CHLAMYDIA ANTIGENS - There is provided a composition for inducing an immune response to a 02-02-2012
20130195907OMV VACCINES - The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of 08-01-2013
20120034257METHYLATED HEPARIN-BINDING HEMAGGLUTININ RECOMBINANT MYCOBACTERIAL ANTIGEN, PREPARATION METHOD AND IMMUNOGENIC COMPOSITIONS COMPRISING SAME - The invention concerns a methylated immunogenic recombinant peptide sequence comprising mycobacterial heparin-binding hemagglutinin. The invention also concerns chemical and enzymatic methods for preparing such a sequence, the sequence being previously produced in a non-methylated recombinant form then methylated by post-translational modification. The invention further concerns recombinant tools, vectors and host cells for implementing post-translational enzymatic methylation of the recombinant HBHA. The invention finally concerns immunogenic compositions comprising methylated, native or recombinant HBHA, such compositions being useful for preparing vaccines against mycobacterial infections.02-09-2012
20120087939METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING SHIGA TOXIN-PRODUCING ESCHERICHIA COLI INFECTION - Compositions and methods for stimulating an immune response against Shiga toxin-producing 04-12-2012
20130209500IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two 08-15-2013
20130209501Immunogenic Compositions of Staphylococcus Epidermidis Polypeptide Antigens - The present invention relates to immunogenic compositions, comprising polypeptides isolated from 08-15-2013

Patent applications in class Disclosed amino acid sequence derived from bacterium (e.g., Mycoplasma, Anaplasma, etc.)